Penthotal

Phase 3Small molecule

RRennes University Hospital

Penthotal is one of 31 small molecule programs targeting Oxidative Stress. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oxidative StressActive, not recruiting

Oxidative StressPhase 3

Active, not recruiting

Competition

Competitive Landscape

138 competitors in Oxidative Stress

#DrugCompanyPhaseTrials

Kerendia

Bayer

Phase 3

1 2

Qvar

SSchering-Plough

Phase 3

1 3

Ascorbate

FFudan University

Phase 3

1 4

Omega 3

MMassachusetts General Hospital

Phase 3

1 5

Niacin/laropiprant

Merck & Co.

Phase 3

1 6

Pterostilbene

UUniversity of Mississippi Medical Center

Phase 3

1 7

Honey

SSohaib Ashraf

Phase 3

1 8

Penthotal

RRennes University Hospital

Phase 3

1 9

Bayer Aspirin

Bayer

Preclinical

1 10

Nicorette

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxidative Stress1 trial

Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy

Completed·RRennes University Hospital·Phase 3·NCT00219856·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Penthotal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Penthotal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Penthotal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rennes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRennes University Hospital

Penthotal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oxidative Stress1 trial

References

Drug Info

Quick Facts

Related News